Botox rival from Revance gets U.S. approvalFDA/Regulatory, TherapeuticsThe U.S. Food and Drug Administrationon Thursday approved Revance Therapeutics’ anti-wrinkle injection, setting up a challenger for market leader AbbVie’s Botox that has long dominated the aesthetic market. Read more September 8, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2022/09/Daxxify9-8-2022.jpg 2160 1559 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-09-08 09:28:422022-09-08 11:02:23Botox rival from Revance gets U.S. approval
